| Literature DB >> 36158272 |
Gianpaolo Vidili1, Marco Arru2, Giuliana Solinas3, Diego Francesco Calvisi2, Pierluigi Meloni2, Assunta Sauchella2, Davide Turilli2, Claudio Fabio2, Antonio Cossu2, Giordano Madeddu2, Sergio Babudieri2, Maria Assunta Zocco4, Giovanni Iannetti5, Enza Di Lembo5, Alessandro Palmerio Delitala2, Roberto Manetti2.
Abstract
BACKGROUND: Contrast-enhanced ultrasound (CEUS) is considered a secondary examination compared to computed tomography (CT) and magnetic resonance imaging (MRI) in the diagnosis of hepatocellular carcinoma (HCC), due to the risk of misdiagnosing intrahepatic cholangiocarcinoma (ICC). The introduction of CEUS Liver Imaging Reporting and Data System (CEUS LI-RADS) might overcome this limitation. Even though data from the literature seems promising, its reliability in real-life context has not been well-established yet. AIM: To test the accuracy of CEUS LI-RADS for correctly diagnosing HCC and ICC in cirrhosis.Entities:
Keywords: Cirrhosis; Contrast-enhanced ultrasound; Contrast-enhanced ultrasound Liver Imaging Reporting and Data System; Hepatocellular carcinoma; Intrahepatic cholangiocarcinoma; Liver
Mesh:
Substances:
Year: 2022 PMID: 36158272 PMCID: PMC9346460 DOI: 10.3748/wjg.v28.i27.3488
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.374
Figure 1Flow chart of the study.
Characteristics of patients and hepatic nodules
|
|
|
| Nodules, | 511 |
| Patients, | 269 |
| Males, | 219 (81.4) |
| Females, | 50 (18.6) |
| Median age at first nodule (IQR; range) | 69 years (61-75; 43-88) |
| Males (IQR; range) | 67 years (59-74; 43-88) |
| Females (IQR; range) | 74.5 years (71-78; 59-85) |
| Hepatic cirrhosis aetiology (n) | |
| Chronic HCV infection, | 129 (48) |
| Alcohol abuse, | 45 (16.7) |
| Chronic HBV infection, | 24 (8.9) |
| Chronic HCV infection + alcohol abuse, | 21 (7.8) |
| Chronic HBV + HCV infection, | 8 (3) |
| NASH, | 6 (2.2) |
| ChronicHBV infection + alcohol abuse, | 5 (1.9) |
| Other aetiologies, | 6 (2.2) |
| Unknown aetiology, | 25 (9.3) |
| Median diameter of nodules (IQR; range) | 24 mm (16-36; 5-200) |
IQR: Inter quartile range; HCV: Hepatitis C virus; HBV: Hepatitis B virus; NASH: Non-alcoholic steatohepatitis.
Rates of different conclusive diagnoses for each Contrast-enhanced ultrasound Liver Imaging Reporting and Data System class
|
|
| |||||||
|
|
|
|
|
|
| |||
| CEUS LI-RADS class | CEUS LR-M | 11 | 21 | 3 | 1 | 1 | 37 | 7.2 |
| CEUS LR-5 | 286 | 0 | 0 | 0 | 2 | 288 | 56.4 | |
| CEUS LR-4 | 111 | 0 | 0 | 0 | 3 | 114 | 22.3 | |
| CEUS LR-3 | 15 | 2 | 0 | 2 | 47 | 66 | 12.9 | |
| CEUS LR-2 | 0 | 0 | 0 | 0 | 5 | 5 | 1.0 | |
| CEUS LR-1 | 0 | 0 | 0 | 0 | 1 | 1 | 0.2 | |
| Total | 423 | 23 | 3 | 3 | 59 | 511 | 100.0 | |
| % | 82.8 | 4.5 | 0.6 | 0.6 | 11.5 | 100.0 | ||
CEUS LI-RADS: Contrast-enhanced ultrasound Liver Imaging Reporting and Data System; HCC: Hepatocellular carcinoma; ICC: Intrahepatic cholangiocarcinoma.
Rates of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in different Contrast-enhanced ultrasound Liver Imaging Reporting and Data System classes
|
|
|
|
| LR-3 | 15/66 (22.7%) | 2/66 (3%) |
| LR-4 | 111/114 (97.4%) | 0/114 (0%) |
| LR-5 | 286/288 (99.3%) | 0/288 (0%) |
| LR-M | 11/37 (29.7%) | 21/37 (56.8%) |
CEUS LI-RADS: Contrast-enhanced ultrasound Liver Imaging Reporting and Data System; HCC: Hepatocellular carcinoma; ICC: Intrahepatic cholangiocarcinoma.
Rates of different contrast-enhanced ultrasound patterns in arterial phase
|
|
|
| Homogeneous hyperenhancement | 404 (79.1) |
| Rim hyperenhancement | 23 (4.5) |
| Globular hyperenhancement | 1 (0.2) |
| Isoenhancement | 65 (12.7) |
| Hypoenhancement | 18 (3.5) |
CEUS: Contrast-enhanced ultrasound.
Rate of different portal and late phase contrast-enhanced ultrasound patterns
|
|
|
| Late and mild washout | 310 (60.7%) |
| Early/marked washout | 27 (5.3%) |
| Isoenhancement | 157 (30.7%) |
| Hypoenhancement | 15 (2.9%) |
| Hyperenhancement | 2 (0.4%) |
CEUS: Contrast-enhanced ultrasound.
Figure 2Examples of different contrast-enhanced ultrasound Liver Imaging Reporting and Data System classes. A: Contrast-enhanced ultrasound (CEUS) LR-M. Notice rim arterial phase hyperenhancement and early washout, before 60 s; B: CEUS LR-5. Notice homogeneous arterial phase hyperenhancement, isoenhancement in portal phase, and mild washout in the late phase; C: CEUS LR-4. Notice homogeneous arterial phase hyperenhancement and isoenhancement in both portal and late phases; D: CEUS LR-3 iso-iso. Notice isoenhancement in all phases; E: CEUS LR-3 hypo-hypo. Notice hypoenhancement in all phases. The arrows show the target lesion.
Diagnostic statistics of different contrast-enhanced ultrasound Liver Imaging Reporting and Data System classes for different diagnosis
|
|
|
|
|
|
|
|
|
|
| CEUS LR M-ICC | 91.3 (72.0-98.9) | 96.7 (94.7-98.1) | 56.8 (39.5-72.9) | 99.6 (98.5-99.9) | 96.5 (94.5-97.9) | 0.880 | 309.75 | < 0.001 |
| CEUS LR 5-HCC | 67.6 (62.9-72.1) | 97.7 (92.0-99.7) | 99.3 (97.5-99.9) | 38.6 (32.1-45.3) | 72.8 (68.7-76.6) | 0.653 | 89.80 | < 0.001 |
| CEUS LR 4-HCC | 26.2 (22.1-30.7) | 96.6 (90.4-99.3) | 97.4 (92.5-99.5) | 21.4 (17.5-25.8) | 38.4 (34.1-42.7) | 0.228 | 10.10 | < 0.001 |
| CEUS LR 4/5-HCC | 93.9 (91.1-95.9) | 94.3 (87.2-98.1) | 98.8 (97.1-99.6) | 76.1 (67.0-83.8) | 93.9 (91.5-95.8) | 0.882 | 253.50 | < 0.001 |
| CEUS LR 3-benign lesion | 79.7 (67.2-89.0) | 95.8 (93.5-97.5) | 71.2 (58.7-81.7) | 97.3 (95.3-98.6) | 93.9 (91.5-95.8) | 0.755 | 89.26 | < 0.001 |
| CEUS LR-3-malignancy | 4.2 (2.5-6.5) | 20.3 (11.0-32.8) | 28.8 (18.3-41.3) | 2.7 (1.4-4.7) | 6.0 (4.2-8.5) | -0.755 | 0.01 | < 0.001 |
| CEUS LR-3-iso-iso-malignancy | 5.3 (0.1-26.0) | 19.1 (9.1-33.3) | 2.6 (0.1-13.5) | 33.3 (16.5-54.0) | 15.2 (7.5-26.1) | -0.756 | 0.01 | < 0.001 |
| CEUS LR-3-hypo-hypo-malignancy | 57.9 (33.5-79.7) | 91.5 (79.6-97.6) | 73.3 (44.9-92.2) | 84.3 (71.4-93.0) | 81.8 (70.4-90.2) | 0.494 | 14.78 | < 0.001 |
CEUS: Contrast-enhanced ultrasound; HCC: Hepatocellular carcinoma; ICC: Intrahepatic cholangiocarcinoma; PPV: Positive predictive value; NPV: Negative predictive value.
Classification of nodules for LR-3, LR-4, and LR-5 classes, reported in yellow, orange, and red, respectively
|
|
|
|
| ||
|
|
|
|
| ||
| No washout of any type | 37 (4) | 21 (5) | 1 (1) | 106 (104) | 165 |
| Late and mild washout | 7 (5) | 8 (7) | 0 | 288 (286) | 303 |
| Total | 44 | 29 | 1 | 394 | 468 |
With the exclusion of nodules with rim and peripheral discontinuous globular arterial phase hyper-enhancement belonging to contrast-enhanced ultrasound LR-M and contrast-enhanced ultrasound LR-1 classes, respectively.
Number of hepatocellular carcinomas in brackets. APHE: Arterial phase hyperenhancement.
Figure 3Absolute frequency (n) of malignancies and benign lesions in LR-3 nodules and LR-3 subgroups with different contrast-enhanced ultrasound patterns.
Figure 4Bangdiwala’s agreement charts of the Contrast-enhanced ultrasound Liver Imaging Reporting and Data System class assignments between different raters. In the case of perfect agreement, the k rectangles are represented by perfect squares and the shaded squares determined by the diagonal cell entries are exactly equal to the rectangles; lesser agreement is visualized by comparing the area of the blackened squares to the area of the rectangles. A: Agreement chart between the two internal raters (1 and 2), with the exclusion of LR-1 and LR-2 classes due to their rarity (n = 505); B-D: Agreement charts among the three raters from different centres (2, 3, and 4) for the subgroup of 50 nodules. We list the agreement charts between raters 2 and 3 (B), between raters 2 and 4 (C), and between raters 3 and 4 (D).